US4614731A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Peptide having immunopotentiating activity similar to thymosin alpha1
Assignee: Hoffmann La Roche Inc
•
Filing: 1985-06-10
•
Granted: 1986-09-30
•
Expires: 2005-06-10
Abstract
Abstract A new biologically active polypeptide hormone has been isolated from calf thymosin fraction 5 and has been given the designation thymosin alpha11. The peptide contains seven additional amino acid residues at the carboxy terminus when compared to thymosin alpha1. Thymosin alpha11 is one of several peptides present in thymosin fraction 5 which participate in the regulation, differentiation and function of thymic dependent lymphocytes (T cells). The new peptide is approxomately 16 times as potent in the protection of subject animals against opportunistic infections as thymosin fraction 5 and approximately equal in potency to thymosin alpha1.
Inventors
- 👤 Bernard L. Horecker
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:52
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/57581; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/827; Y10S530/837; Y10S930/00; Y10S930/01; Y10S930/18
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
16 words
A peptide of the sequence: ##STR2## and the pharmaceutically acceptable acid and base addition salts thereof.
Claim 2
Dependent Claim
16 words
A peptide of the sequence: ##STR2## and the pharmaceutically acceptable acid and base addition salts thereof.
Claim 3
Independent Claim
42 words
A method for reconstituting immune functions in thymic deprived or immunodeprived warm-blooded animals which method comprises parenterally administering to such mammal an immunopotentiating effective amount of a peptide having the sequence: ##STR3## or the pharmaceutically acceptable acid and base addition salts thereof.
Claim 4
Independent Claim
42 words
A method for reconstituting immune functions in thymic deprived or immunodeprived warm-blooded animals which method comprises parenterally administering to such mammal an immunopotentiating effective amount of a peptide having the sequence: ##STR3## or the pharmaceutically acceptable acid and base addition salts thereof.
Claim 5
Dependent Claim
26 words
The method of claim 2 wherein a daily dosage in the range of from about 1 to 100 μg/kg of body weight per day is administered.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-09-29 | 1990-03-31 | 1990-09-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-09-29 | 1994-03-31 | 1994-09-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-09-29 | 1998-03-31 | 1998-09-30 | $7700.00 | Window Closed / Lapsed |